Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Dawson

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Hepatology (Baltimore, Md.)|October 21, 2015
Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategiesDavid M Brett-Major, Kevin D Frick, Jennifer A Malia, et al.
The Journal of Infectious Diseases|May 23, 2018
Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)Augustin E Fombah, Susan T Goldstein, Olamide D Jarrett, et al.
The New England Journal of Medicine|May 19, 2016
Prospective Study of Acute HIV-1 Infection in Adults in East Africa and ThailandMerlin L Robb, Leigh A Eller, Hannah Kibuuka, et al.
Military Medicine|July 11, 2020
Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategiesPaul T Scott, Robert L Cohen, David M Brett-Major, et al.
BMJ (Clinical Research Ed.)|March 22, 2017
Urgent improvements needed to diagnose and manage Lynch syndromeKevin J Monahan, Deborah Alsina, Simon Bach, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
The Journal of Infectious Diseases|May 23, 2018
The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola OutbreakMohamed Samai, Jane F Seward, Susan T Goldstein, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Hepatology (Baltimore, Md.)|October 21, 2015
Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategiesDavid M Brett-Major, Kevin D Frick, Jennifer A Malia, et al.
The Journal of Infectious Diseases|May 23, 2018
Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)Augustin E Fombah, Susan T Goldstein, Olamide D Jarrett, et al.
The New England Journal of Medicine|May 19, 2016
Prospective Study of Acute HIV-1 Infection in Adults in East Africa and ThailandMerlin L Robb, Leigh A Eller, Hannah Kibuuka, et al.
Military Medicine|July 11, 2020
Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategiesPaul T Scott, Robert L Cohen, David M Brett-Major, et al.
BMJ (Clinical Research Ed.)|March 22, 2017
Urgent improvements needed to diagnose and manage Lynch syndromeKevin J Monahan, Deborah Alsina, Simon Bach, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
The Journal of Infectious Diseases|May 23, 2018
The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola OutbreakMohamed Samai, Jane F Seward, Susan T Goldstein, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 10